Bio-Gene Technology (ASX:BGT) — Material Events
ASX:BGT · 17 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Bio-Gene Advances Flavocide Toward March 2027 Regulatory SubmissionMedium
Bio-Gene targets March 2027 regulatory submission for novel insecticide Flavocide
3 Mar 2026
·Regulatory Update
·85
Bio-Gene Teams with Sumitomo and Nakashima to Launch Natural Insecticide in JapanMedium
Bio-Gene partners with Sumitomo and Nakashima to launch natural insecticide Qcide® in Japan's $1B household pest market
16 Mar 2026
·Partnership Announcement
·85
Bio-Gene Advances Novel Insecticides Amid Growing Global DemandMedium
Bio-Gene reports strong Q1 FY26 progress with new product opportunities, positive efficacy data, and US DoD grants
31 Oct 2025
·Quarterly Activities Report and Appendix 4C
·80
Bio-Gene Accelerates Insecticide Innovation with US DoD Grants and OMRI ApprovalMedium
Bio-Gene advances insecticide platforms with US DoD grants, OMRI approval, and strong regulatory progress
30 Jan 2026
·Quarterly Activities Report and Appendix 4C
·80
Bio-Gene Secures A$3.21m to Push Flavocide Regulatory Approval and Scale Qcide ProductionMedium
Bio-Gene advances natural insecticides Flavocide and Qcide targeting $44B global markets with key partnerships and US DoD grants
26 May 2026
·Investor Presentation
·80
Bio-Gene’s Qcide® Secures Key Organic Listing, Unlocking US Market PotentialMedium
Bio-Gene's Qcide® gains OMRI organic listing under USDA program, boosting market potential
14 Nov 2025
·Regulatory Approval Announcement
·80
Bio-Gene’s Flavocide Achieves 90% Tick Mortality in Purdue StudyMedium
Bio-Gene's Flavocide Shows Strong Tick Control Efficacy in Purdue University Studies
23 Sept 2025
·ASX Announcement
·80
Bio-Gene Advances Bio-Insecticides with New Data and Organic CertificationMedium
Bio-Gene advances bio-insecticides with regulatory progress, new efficacy data, and organic certification
19 Nov 2025
·Annual General Meeting Chair’s Address
·75
Bio-Gene Advances Natural Insecticides with $31B Market PotentialMedium
Bio-Gene advances natural insecticides Flavocide and Qcide with strong market potential and partnerships
19 Nov 2025
·Annual General Meeting Presentation
·75
Bio-Gene Advances Novel Insecticides Amid Rising Losses and Strategic PartnershipsMedium
Bio-Gene reports 2025 loss, advances insecticide development, secures US DoD grants and expands partnerships
26 Aug 2025
·Annual Report
·75
Bio-Gene Advances Flavocide Registration and Secures Japan Deal for Qcide InsecticideMedium
Bio-Gene advances Flavocide registration, inks Japan Qcide deal, completes 15th harvest
27 Apr 2026
·Quarterly Activities Report and Appendix 4C
·75
Bio-Gene Raises $2.45M to Advance Novel Insecticides and Regulatory MilestonesMedium
Bio-Gene raises $2.45M to advance novel insecticides and regulatory approvals
31 July 2025
·Quarterly Activities Report and Appendix 4C
·75
Bio-Gene Advances Wearable Flavocide and Qcide Spray in US DoD GrantsMedium
Bio-Gene advances US DoD-funded Flavocide wearable and Qcide spray projects
18 Dec 2025
·Progress Update
·70
Bio-Gene Raises A$2.46M in Tranche 2 Placement, Issues Long-Dated OptionsMedium
Bio-Gene completes tranche 2 placement raising A$2.46M and issues options
21 July 2025
·Capital Raising
·70
Bio-Gene Clarifies Timing of Flavocide Results Amid ASX InquiryMedium
Bio-Gene confirms timely disclosure of positive Flavocide efficacy results after ASX query
29 Sept 2025
·ASX Aware Query Response
·70
Bio-Gene Raises $2.775 Million in Placement with Options Awaiting Shareholder NodMedium
Bio-Gene raises $2.775 million via placement with attaching options pending shareholder approval
2 June 2026
·Capital Raising
·70
Bio-Gene Secures $519,500 Boost for Novel Insecticide R&DMedium
Bio-Gene Receives $519,500 R&D Tax Incentive for Novel Insecticide Development
25 Nov 2025
·ASX Announcement
·50
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Bio-Gene Technology (ASX:BGT) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 23 (1 June -> 5 June) 2026
6 June 2026
Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026
Market Wrap - Week 10 (2 Mar -> 6 Mar) 2026
7 Mar 2026